Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HLA class II histocompatibility antigen, DM alpha chain (HLA-DMA) is a non-classical MHC class II alpha chain molecule that forms a heterodimer with HLA-DMB. This complex is localized primarily in intracellular vesicles of antigen-presenting cells (B lymphocytes, dendritic cells, macrophages). HLA-DM catalyzes the exchange and loading of antigenic peptides onto classical MHC class II molecules by promoting the release of the class II-associated invariant chain peptide (CLIP), shaping the repertoire of antigens presented to CD4+ T cells. HLA-DM is essential for effective adaptive immunity and modulates immune surveillance, self-tolerance, and responses to pathogens. Genetic and functional variations in HLA-DMA can influence susceptibility to autoimmune diseases and transplant outcomes, but it is not a common direct therapeutic target[1][2][3][5].
Enhancement of DM-catalyzed peptide exchange (experimental small molecules increase catalytic efficiency, facilitating release of peptide ligands from MHC class II)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HLA class II histocompatibility antigen, DM alpha chain (HLA-DMA).